(TheNewswire)
VANCOUVER, BC / TheNewswire / April 21, 2022 / AREV Life Sciences Global Corp. (CSE:AREV)(OTC:AREVF) ( “ AREV” orthe “ Company ”) AREV announcedtoday its initial research engagement with TransBIOTech.
Created in 1999, TransBIOTech, a publicly-supportedpreclinical research organization that works in partnership with andis supported by the Canadian government through the Natural Sciencesand Engineering Research Council (NSERC) in collaboration with theCanadian Institutes of Health Research (CIHR). TransBIOTech is alsosupported by the Canadian Foundation for Innovation and by theGovernment of Quebec. TransBIOTech is a member of Tech-Access Canada,a national organization of Technology Access Centres (TACs) as well asa member of Synchronex, a network of Quebec province College Centresfor the Transfer of Technologies (CCTT). TransBIOTech laboratoryfacility utilizes more than $16 million in state-of-the-art equipmentand offers an animal facility accredited by the Council on Animal Careof Canada (source: https://www.tbt.qc.ca/en/facilities/).
TransBIOTech is a multi-sectional research facilitywith expertise i n the lifesciences sector, specializing in analytical chemistry, biochemistry,cell & molecular biology, and microbiology for pharmaceuticalsciences. With capabilities in various project stages including invitro, in cellulo, and in vivo functional assays (biomarkers,cytotoxicity, anti-inflammatory properties, and antimicrobial activityas well as analysis of pharmacological properties of molecules(permeability, metabolic stability, ADME and toxicology).
“ TransBIOTech is engaging withAREV in its initial research on cannabinoids and other early-stagecommercial research programs. Our agreement with TransBIOTech signalsthe initiation of a robust clinical initiative with numerouscollaborators to facilitate data on some of the more promisingphytomedicinal therapeutics currently relevant to today ’ s public healthchallenges. ” said MikeWithrow.
Withrow also stated, “ AREV Life Sciences is determined toenhance our scientific acumen by partnering with dynamic programs thatwill facilitate breakthrough discoveries of therapeutic innovationrelevant to contemporary pandemic infectious disease and humannutrition. By leveraging our proprietary extraction technologiespaired with the discovery capacities of TransBIOTech and otherwell-respected research institutions, we are laying the groundwork forinitial animal studies to identify data sets that will satisfyregulatory authorities. ”
Recent preclinical studies have purported that CBDmodulates anti-inflammatory effects. Clinical studies have verifiedthat CBD lowers the levels of pro-inflammatory cytokines, suppresses Tcell proliferation, creates T cell apoptosis and lowers migration andadhesion of immune cells. It has also been discovered that this CBDdriven anti-inflammatory action displays itself to be antagonized byboth a CB2 antagonist and a CB2 receptor agonist (source: https://www.frontiersin.org/articles/10.3389/fphar.2017
.00144/full ). TheTransBIOTech collaboration with AREV will also examine precisemechanisms of action attributed to the activation of CB2 as a noveltherapeutic modality modulating inflammation characteristic of viralinfections (source: https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3005548/ ).
The collaboration between AREV and TransBIOTech will facilitatefurther development of proprietary immune modulatory therapeuticsderived from phytomedicinal research that addresses pandemicinfectious disease affecting host responses to elevated cytokineexpression.
The initial studies will set the groundwork foradvancing further research allowing for distinctive understandings ofAREV ’ s new chemicalentity development including initial toxicity, pharmacokinetics andmetabolism modeling essential for human studies and eventualcommercialization. The reduction of pathogenmediated inflammation and subsequent immune hyperactivation by theinhibition of the mTOR/S6K-signaling progression which is affected bycannabinoids CB1 receptor also prohibits Jurkat cells from expressingregulation of immune responses (source: https://www.nature.com
/articles/4401660 ). Invivo studies have demonstrated mTOR expression affected by cannabinoidregulatory mechanisms leading to autophagy in cancer cell pathwaysnecessary for the antitumor actions (source: https://www.jci.org/articles/view/37948 ).
AREV, in conjunction with TransBIOTech, is alsodesigning preclinical characterization studies to identify suspectedtherapeutic characteristics of other botanically-derived compoundsidentified in peer-reviewed literature including phytocannabinoids andCucumaria frondosa leading to small molecule candidates for human studies.
Edouard Lauzer, of TransBioTech stated, “ Our preclinical characterizationresearch with TransBIOTech is an important step in AREV ’ s efforts to deliver well-definedclinical insights into the multi-dimensional aspects of immunemodulation associated with CBD and other compounds derived fromphytomedicinal drug development. AREV ’ s efforts with TransBIOTech willinclude characterizing the mechanism-of-action of CBD as well asanalysis of the structure-activity relationships of secondarymetabolites through fragment-based lead discovery and de novo drug design,utilizing high through-put screening to identify structural-functionalrelations of AREV ’ sinvestigational compounds affecting pathogen-mediated inflammation andviral replication.
The initial studies being designed by TransBIOTech, incollaboration with members of the AREV Scientific Advisory Board(SAB), will provide correspondence of the subsequent published resultsof these studies to public research programs including The NationalInstitute of Health ’ sAccelerating Covid-19 Therapeutic Interventions and Vaccines (NIHACTIV), AIDS Clinical Trial Groups (NIAID ACTGs) of the NationalInstitute of Allergy and Infectious Diseases and PresidentBiden ’ s White HouseCancer Cabinet.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
ABOUT AREV LifeSciences Global Corp.
AREV Life Sciences Global Corp. a publicly traded,fully integrated, early-stage life science enterprise, with a USsubsidiary dedicated to delivering therapeutic interventions to publichealth through extraction of unique compounds, discovery, innovationand successful collaborations. The company ’ s leadership drives discoveryprograms for clinical complexities presented by malnutrition, viralinfectious diseases, and elevated inflammatory responses . AREV is invested in commercialinnovations in phytomedicinal discoveries of small molecule antiviralsand for related neglected chronic co-morbidities and innovations inhuman nutrition. In addition to its phytomedicinal discovery program,AREV is developing a next generation Ready-to-Use Therapeutic Food(RUTF). SUSTAINN is designed by AREV in collaboration with theRichardson Centre for Functional Foods and Nutraceuticals at theUniversity of Manitoba that demonstrates clinical attributesaddressing serious acute malnutrition (SAM). AREV is dedicated todesigning and delivering innovation in rational drug design, driven bypresenting global epidemiological characteristics of multiplechallenges to international human and animal health. AREV is a memberof both BIOTECanada and The Biotechnology Innovation Organization(BIO).
This press releasecontains forward-looking statements within the meaning of applicablesecurities laws. All statements that are not historical facts,including without limitation, statements regarding future estimates,plans, programs, forecasts, projections, objectives, assumptions,expectations or beliefs of future performance, are “forward-lookingstatements.” Forward-looking statements can be identified by the useof words such as “plans”, “expects” or “does not expect”,“is expected”, “estimates”, “intends”, “anticipates”or “does not anticipate”, or “believes”, or variations of suchwords and phrases or statements that certain actions, events orresults “may”, “could”, “would”, “might” or “will”be taken, occur or be achieved. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors thatmay cause actual results, events or developments to be materiallydifferent from any future results, events or developments expressed orimplied by such forward looking statements.
THE CSE HAS NEITHERAPPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOTACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.
Copyright (c) 2022 TheNewswire - All rights reserved.